Case report and literature review of BRAF‐V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift. (12th January 2022)

• Record Type: Journal Article
• Authors: Nussbaum, Penelope E.; Nussbaum, Leslie A.; Torok, Collin M.; Patel, Puja D.; Yesavage, Tiffany A.; Nussbaum, Eric S.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 47:Number 6(2022)
• Page Start: 826
• Page End: 831
• Publication Date: 2022-01-12
• Subjects: BRAF‐V600E -- case report -- dabrafenib -- papillary craniopharyngioma -- trametinib; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.13600
• Languages: English
• ISSNs: 0269-4727

Abstract

Abstract: What is known and objective: The BRAF ‐ V600E genetic mutation offers a potential targeted therapy for the treatment of papillary craniopharyngiomas. Case summary: A 35‐year‐old man underwent a craniotomy and subtotal resection of a large BRAF ‐ V600E ‐positive papillary craniopharyngioma before referral to our institution. Our treatment included the BRAF‐V600 inhibitor dabrafenib mesylate (75 mg, twice/day) and trametinib dimethyl sulfoxide (2 mg/day). The residual tumour decreased in size by 95% over 21 months without negative side effects. What is new and conclusion: We reviewed the literature on BRAF‐V600E inhibition as a non‐invasive method of treating papillary craniopharyngiomas harbouring the BRAF ‐ V600E mutation.